Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.19, sa.2, ss.108-112, 2011 (Scopus)
Purpose: To evaluate the functional and anatomical results after intravitreal ranibizumab injection in patients with macular edema secondary to retinal vein occlusion. Materials and Methods: Twenty-one eyes of 20 patients with macular edema secondary to retinal vein occlusion were treated with intravitreal ranibizumab injections (0.5 mg/0.05 ml) and enrolled in the study. These patients were evaluated with logMAR visual acuity, biomicroscopy, intraocular pressure, and optical coherence tomography results before the first injection, and at 1st and 3rd months and at the last control after injections. Results: Twenty-one eyes of 20 patients with a mean age of 60.8 years (45-86) were studied. Of the patients, 10 had central retinal vein occlusion and 11 had branch retinal vein occlusion. The mean logMAR visual acuity was 1.00±0.5 before the injection, while it was 0.84±0.5, 0.83±0.6, and 0.80±0.6, at the 1 month, 3 month, and last control, respectively. There was a statistically significant visual acuity improvement during follow-up (p<0.05, Wilcoxon signed-rank test). Optical coherence tomography scans revealed that mean central macular thickness was 682.23±347.2 μm before the injections and 359.17±202.16 μm after the injections of 17 eyes (p<0.05, Wilcoxon signed-rank test). Mean follow-up was 7.28 months and mean injection number during this period was 2.74 for these patients. Conclusion: In the short term, macular edema decreased and visual acuity increased after intravitreal injection of ranibizumab in cases of retinal vein occlusion. However, long-term studies are needed to examine the permanency of this anatomical and functional recovery.